ReviewAnti-cancer agents in medicinal chemistry2010
Pharmacogenomics of human ABC transporter ABCC11 (MRP8): potential risk of breast cancer and chemotherapy failure.
Review in Anti-cancer agents in medicinal chemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- Human Body Malodor and Deodorants: The Present and the Future.International journal of molecular sciences · 2025Review
- Interplay of human ABCC11 transporter gene variants with axillary skin microbiome functional genomics.Scientific reports · 2024Article
- Mechanism of 5-fluorouracil induced resistance and role of piperine and curcumin as chemo-sensitizers in colon cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers.Cancers · 2021Review
- Clioquinol: To harm or heal.Pharmacology & therapeutics · 2019Review
- MED23 in endocrinotherapy for breast cancer.Oncology letters · 2017Article
- Functional characterization of common protein variants in the efflux transporter ABCC11 and identification of T546M as functionally damaging variant.The pharmacogenomics journal · 2016Article
- Diagnosis of Human Axillary Osmidrosis by Genotyping of the Human ABCC11 Gene: Clinical Practice and Basic Scientific Evidence.BioMed research international · 2016Review
- Regulation of the Axillary Osmidrosis-Associated ABCC11 Protein Stability by N-Linked Glycosylation: Effect of Glucose Condition.PloS one · 2016Article
- ABCC11/MRP8 Expression in the Gastrointestinal Tract and a Novel Role for Pepsinogen Secretion.Acta histochemica et cytochemica · 2014Article
- Glutathione-conjugated sulfanylalkanols are substrates for ABCC11 and γ-glutamyl transferase 1: a potential new pathway for the formation of odorant precursors in the apocrine sweat gland.Experimental dermatology · 2014Article
- Localization of multidrug resistance-associated proteins along the blood-testis barrier in rat, macaque, and human testis.Drug metabolism and disposition: the biological fate of chemicals · 2014Article
- Membrane transporters in a human genome-scale metabolic knowledgebase and their implications for disease.Frontiers in physiology · 2014Review
- Eradication of Human Ovarian Cancer Cells by Transgenic Expression of RecombinantJournal of genetic syndromes & gene therapy · 2013Article
- Dependence of deodorant usage on ABCC11 genotype: scope for personalized genetics in personal hygiene.The Journal of investigative dermatology · 2013Article
- Pharmacogenomics of phase II metabolizing enzymes and drug transporters: clinical implications.The pharmacogenomics journal · 2013Review
- High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival.Breast cancer research and treatment · 2013Article
- Pharmacogenetics of human ABC transporter ABCC11: new insights into apocrine gland growth and metabolite secretion.Frontiers in genetics · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Some genetic polymorphisms of human ABC transporter genes are reportedly related to the risk of certain diseases and patients' responses to medication. Human ABCC11 functions as an ATP-dependent efflux pump for amphipathic anions. One non-synonymous SNP 538G>A (Gly180Arg) has been found to greatly affect the function and stability of de novo synthesized ABCC11 (Arg180) variant protein. The SNP variant lacking N-linked glycosylation is recognized as a misfolded protein in the endoplasmic reticulum (ER) and readily undergoes proteasomal degradation. This ER-associated degradation of ABCC11 protein underlies the molecular mechanism of affecting the function of apocrine glands. On the other hand, the wild type (Gly180) of ABCC11 is associated with wet-type earwax, axillary osmidrosis, colostrum secretion from the mammary gland, and the potential susceptibility of breast cancer. Furthermore, the wild type of ABCC11 reportedly has ability to efflux cyclic nucleotides and nucleoside-based anticancer drugs. The SNP (538G>A) of the ABCC11 gene is suggested to be a clinical biomarker for prediction of chemotherapeutic efficacy. Major obstacle to the successful chemotherapy of human cancer is development of resistance, and nucleoside-based chemotherapy is often characterized by inter-individual variability. This review provides an overview about the discovery and the genetic polymorphisms in human ABCC11. Furthermore we focus on the impact of ABCC11 538G>A on the apocrine phenotype, patients' response to nucleoside-based chemotherapy, and the potential risk of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.